Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis PR Newswire - Tue Aug 25, 7:30AM CDT

REZOLVE-AD study met all primary and key secondary endpoints, including   EASI-75,   EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w

NKTR : 74.55 (+1.06%)
Nektar: Q2 Earnings Snapshot AP - Thu Aug 13, 3:32PM CDT

Nektar: Q2 Earnings Snapshot

NKTR : 74.55 (+1.06%)
Nektar Therapeutics Announces Second Quarter 2026 Financial Results PR Newswire - Thu Aug 13, 3:15PM CDT

SAN FRANCISCO , Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial...

NKTR : 74.55 (+1.06%)
Nektar's Phase Three Timeline Assumes a Regulatory Path That May Not Exist Barchart - Wed Aug 12, 4:06PM CDT

Barchart Research What to Expect from NKTR Earnings NKTR Generated August 12, 2026 Current Price $76.03 EPS Estimate $$-2.06 Consensus Rating Strong Buy Average Move 3.67% Nektar's Phase Three Timeline...

NKTR : 74.55 (+1.06%)
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm PR Newswire - Tue Aug 11, 6:50AM CDT

NEW YORK , Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) ...

NKTR : 74.55 (+1.06%)
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets PR Newswire - Tue Jul 28, 5:00PM CDT

SAN FRANCISCO , July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after...

NKTR : 74.55 (+1.06%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Jul 24, 3:15PM CDT

SAN FRANCISCO , July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 74.55 (+1.06%)
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis PR Newswire - Tue Jul 21, 6:00AM CDT

Two global registrational Phase 3 trials initiated in ZENITH AD program

NKTR : 74.55 (+1.06%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Jun 26, 3:30PM CDT

SAN FRANCISCO , June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 74.55 (+1.06%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Wed Jun 3, 3:15PM CDT

SAN FRANCISCO , June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 74.55 (+1.06%)

Barchart Exclusives

Potential Bidders Are Looking at Shell’s Chemical Assets. How Investors Should View a Potential Sale. Barchart - Thu Aug 27, 6:30PM CDT
Potential bidders including ExxonMobil and LyondellBasell are looking at Shell’s U.S. chemicals assets in a deal that could fetch up to $8 billion. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.